The results of this study provide early, preclinical evidence that the assessment of IGF2BP3 expression combined with the IGF1R/IR ratio may be used to predict therapeutic responses to the dual IGF1R/IR inhibitor OSI-906, providing new insights for a more precise and rational administration of anti-IGF system agents in ES. Here, INSR is linked to Ewing sarcoma.